Recommendations Regarding ART Initiation for Asymptomatic People
Of the 70 countries reviewed, 42 (60%) are similar with the 2010 WHO ART guidelines and recommend ART at CD4 count of ≤350 cells/mm3 for asymptomatic people. They include Guinea, France, Italy, and Uruguay, which also consider ART for asymptomatic people with CD4 counts between 350 cells/mm3 and 500 cells/mm3. Fourteen countries updated their guidelines to recommend ART at CD4 count ≤350 cells/mm3 before 2010 (Fig. 1). Other countries are not consistent with WHO recommendations. Five (7%) of the 70 countries recommend ART at CD4 count ≤250 cells/mm3; 19 (27%) countries recommend ART at CD4 count ≤200 cells/mm3, 5 of which also recommend considering ART at CD4 count of ≤350 cells/mm3. Three (4%) countries (Algeria, Argentina, and Bolivia) recommend ART at CD4 count ≤500 cells/mm3. Bolivia and Italy additionally consider ART at CD4 count ≥500 cells/mm3 if good adherence can be maintained. In 2012, the United States recommended ART for all people living with HIV irrespective of CD4 count.
Recommendations Regarding ART Initiation for People With HIV and TB
Of the 70 countries, 23 (33%) countries are consistent with WHO recommendation for ART irrespective of CD4 count for people coinfected with HIV and TB. In 24 (34%) countries, ART is recommended only for a CD4 count of ≤350 cells/mm3. These include (a) Zambia that additionally recommends ART at CD4 count ≥350 cells/mm3 for people with HIV, TB, and other WHO clinical stage III or IV illnesses; (b) Myanmar and Ethiopia, where ART is recommended irrespective of CD4 cell count only for people living with HIV and extrapulmonary or disseminated TB; (c) South Africa, where ART irrespective of CD4 cell count for HIV-positive people with drug-resistant TB is an additional recommendation. One country (Comoros) recommends ART for people with HIV and TB at CD4 count ≤200 cells/mm3. The remaining 22 (31%) of 70 countries do not mention ART eligibility criteria for people with HIV-associated TB and can be presumed to not be providing ART to all using active TB as a criterion.
Recommendations Regarding ART Initiation for Pregnant Women
A total of 31 countries (44%) are consistent with WHO ART guidelines and recommend ART at CD4 count ≤350 cells/mm3, of which France also considers ART for pregnant women with CD4 count ≤500 cells/mm3. Of the 70 countries, 10 (14%) countries have adopted Option B+ and recommend life-long ART irrespective of CD4 count. Thailand recommends ART irrespective of CD4 count in pregnant women but those with pretreatment CD4 count ≥350 cells/mm3 stop ART after delivery. Argentina considers ART at CD4 count ≥500 cells/mm3. ART at CD4 count ≤250 cells/mm3 is recommended by 5 (7%) countries, including Vietnam that additionally recommends ART at CD4 count ≤350 cells/mm3 for pregnant women with WHO stage 3 illnesses. Eleven (16%) countries recommend ART at CD4 count ≤200 cells/mm3 including (a) Cape Verde that also considers ART at CD4 count ≤350 cells/mm3 and (b) Myanmar that additionally recommends ART at CD4 count ≤350 cells/mm3 in pregnant women with WHO stage 3 illnesses. The remaining 11 (16%) countries do not have specific ART initiation guidelines for pregnant women.
Recommendations Regarding ART Initiation for Serodiscordant Couples
There are 13 countries with recommendations on use of ART in serodiscordant couples (Fig. 2). Britain, Thailand, and Nigeria recommend initiating ART at CD4 count ≥350 cells/mm3 and are consistent with WHO couples HIV testing and counseling guidelines; Mexico recommends ART for HIV-positive partners in serodiscordant couples with CD4 count between 350 cells/mm3 and 500 cells/mm3. The United States, Algeria, Canada, Italy, Venezuela, Uruguay, and Zambia recommend initiating ART irrespective of CD4 count for serodiscordant couples. Argentina and France recommend ART for HIV-positive partner at CD4 count ≥500 cells/mm3.
Although Burundi does not mention guidelines for serdiscordant couples, ART irrespective of CD4 count is recommended for HIV-positive partners of HIV-negative pregnant women. Malawi recommends initiating life-long ART irrespective of CD4 count in HIV-positive pregnant and breastfeeding women, one of the rationale being that it will prevent HIV transmission in serodiscordant couples.
Recommendations Regarding ART Initiation for IDUs, MSM, and Sex Workers
Although WHO recognizes their vulnerability and need for access to services, WHO uses immunological criteria and does not make specific recommendations regarding ART eligibility for specific at-risk populations. None of the countries reviewed have specific recommendations regarding ART for commercial sex workers, IDUs, and MSM. Guyana, Myanmar, and Vietnam recommend ART for IDUs at CD4 count levels recommended for other people living with HIV.
ART Eligibility Criteria in the WHO/UNAIDS Priority Countries
In the 28 priority countries [Brazil, Botswana, Cambodia, Cameroon, Caribbean (from the 2005 regional guidelines), China, Democratic Republic of Congo, Ethiopia, India, Indonesia, Ivory Coast, Kenya, Lesotho, Malawi, Mozambique, Myanmar, Namibia, Nigeria, Russia, Rwanda, South Africa, Swaziland, Tanzania, Thailand, Uganda, Ukraine, Zambia, and Zimbabwe] with an estimated 85% burden of HIV/TB, 16 (57%) countries recommend ART at CD4 count ≤350 cells/mm3 for asymptomatic people living with HIV. Three (11%) countries (Botswana, Mozambique, and Uganda) recommend ART at CD4 count ≤250 cells/mm3. The remaining 9 (32%) countries recommend ART for HIV-positive asymptomatic people at CD4 count ≤200 cells/mm3, of which Russia and Ukraine also consider ART at CD4 count ≤350 cells/mm3. For people living with HIV and TB, 13 (46%) countries recommend ART initiation irrespective of CD4 count; 10 (36%) countries recommend ART at CD4 count ≤350 cells/mm3. The remaining 5 (18%) countries do not have guidelines for this target population. In the 22 countries (Angola, Botswana, Burundi, Cameroon, Chad, Ivory Coast, Democratic Republic of the Congo, Ethiopia, Ghana, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Swaziland, Uganda, Tanzania, Zambia, and Zimbabwe) with the highest estimated numbers of pregnant women living with HIV, 14 (64%) countries are consistent with WHO guidelines and recommend ART at CD4 count ≤350 cells/mm3. ART eligibility criteria are ≤250 CD4 cells/mm3 in Botswana and ≤200 CD4 cells/mm3 in 3 countries (Cameroon, Ethiopia, and Ivory Coast). Malawi recommends ART irrespective of CD4 count for pregnant women for life.
ART Eligibility Criteria and Coverage of ART
In the 66 countries with coverage data, an estimated 48% of the people eligible for ART at CD4 count ≤350 cells/mm3 were receiving it in 2010. Three countries with generalized epidemic (Botswana, Namibia, and Rwanda) and 7 countries with concentrated or low-level epidemic (Britain, Cambodia, Chile, Cuba, Guyana, Nicaragua, and Spain) have achieved universal access to ART. Coverage was below 50% in 30 (43%) countries in 2010. The published ART eligibility criteria and ART coverage across countries are positively but weakly correlated to income levels (Fig. 3). The degree of dispersion in coverage levels is substantially higher among lower income countries. Although some of them have achieved universal access targets, coverage rates in 2010 were extremely low in others. Similarly, the current ART eligibility criteria differs more among the low- and middle-income countries; all high-income countries are recommending ART for asymptomatic people at CD4 count ≤350 cells/mm3 or earlier.
The multiple regression analysis (Table 2) shows that, even though higher income countries seem more likely to be consistent with WHO guidelines or even recommend earlier ART, the effect of per capita income is not statistically significant (P < 0.53). ART eligibility criterion is significantly associated with HIV prevalence, HIV expenditure, and year of publication of guidelines. The probability of consistency with WHO recommendation is higher in countries with low HIV prevalence and greater HIV expenditure. On the other hand, results from regression of Equation (2) show that ART coverage is significantly associated with per capita income and HIV expenditure but not other factors (Table 2). In 2010, the average ART coverage was higher in countries recommending ART at CD4 count ≤350 cells/mm3 or earlier, but it was statistically indifferent from coverage rates in countries below the WHO recommendation.
In the 30 years since the start of HIV pandemic, over 30 million people have died,1,18,19 with TB being the leading cause of death despite being preventable and curable.20 ART has considerable potential to save lives and prevent HIV and TB.3–7 WHO’s 2010 ART guidelines reflect the evidence that starting ART at CD4 count ≤350 cells/mm3 is cost-effective, improves health outcomes, and reduces HIV and TB transmission.21,22 Emerging evidence from observational studies4,23 and the HIV Prevention Trials Network 052 randomized-controlled trial (which showed a 96% reduction in HIV transmission in serodiscordant couples initiating ART at CD4 counts between 350 and 550 cells/mm3)7 led WHO to also recommend ART at CD4 count ≥350 cells/mm3 for serodiscordant couples. Our review found that guidelines in many countries are consistent with the WHO recommendations on ART initiation for asymptomatic people, pregnant women, and people coinfected with HIV and TB. Policy adaptation is a dynamic process, and although the WHO couples HIV testing and counselling guidelines and programmatic update on prevention of mother-to-child transmission were released in 2012, some countries were already recommending Option B+ for pregnant women and ART for serodiscordant couples.
Our review shows that 60% of the national guidelines are consistent with the WHO recommendations for treatment eligibility for asymptomatic people. However, some countries have opted for earlier treatment in general population after weighing evidence from large observational studies from America, Europe, and Australia, which have demonstrated the benefits of early ART at CD4 count ≥350 cells/mm3. The results from ART cohort collaboration (ART-CC), collaboration of North American cohort studies (NA-ACCORD), and HIV Cohorts Analyzed Using Structural Approaches to Longitudinal data (HIV-CAUSAL collaboration) suggest that initiating ART at CD4 counts between 350 and 500 cells/mm3 is associated with lower risk of AIDS-defining illnesses.24–26 Additional national policy shifts to earlier access to ART are in progress and reflect the recent results from the HIV Prevention Trials Network 052 randomized clinical trial in developing country settings. It found that starting ART at CD4 count ≤550 cells/mm3 was significantly associated with fewer adverse clinical events when compared with those who started later.7 In contrast, many low-income countries in high-burden areas have yet to change their published eligibility criteria from CD4 cell counts of ≤200 cells/mm3 or ≤250 cells/mm3.
WHO is a member state organization, and its recommendations represent the outcome of the policy feedback loop whereby inputs from national programs are used to formulate global recommendations. National policies, while reflecting WHO and other guidelines, have also been influenced by the emerging scientific evidence and recommend early ART for preventing HIV morbidity, mortality, and transmission. As part of its routine normative role, WHO will systematically review the evidence on when to start ART for the guidelines update in 2013. Although the prevention and economic benefits of starting ART at a CD4 count ≤350 cells/mm3 are well established, program managers have to also take into account programmatic and operational considerations that may either limit expansion or push them to invest more heavily in their ART expansion efforts to realize greater health and prevention benefits. Our statistical analysis also establishes the significant association of ART eligibility criteria with HIV prevalence and HIV expenditure. There is a large variation in the published ART recommendation among poorer countries and all the countries below the WHO recommendation are in low-income bracket. Findings in this analysis can be used to help benchmark the current pace of policy adaptation and help guide the revision and dissemination of national ART recommendations to keep pace with the available science.
Despite the existence of clear national policy, there are often significant gaps in the implementation of these guidelines. Even though substantial progress has been made in providing ART to people living with HIV over the last decade, the estimated global coverage in the countries analyzed was still less than 50% in 2010. Statistically, the 2010 coverage levels are significantly associated with per capita income and HIV expenditure. Even though the correlation between ART coverage and per capita income is positive, many low-income countries have been able to approach levels of coverage of countries with higher income levels. The barriers preventing the poorer countries from achieving universal access targets are lack of awareness about HIV status, weak health systems, and social marginalization of people living with HIV.27 Further research is required to monitor and evaluate the extent of implementation of the guidelines and determine the barriers to ART scale-up in individual countries.
Our policy review has several limitations. Our analysis is restricted to the latest available guidelines from 70 countries. In addition, these guidelines maybe outdated or in the process of being updated especially after recent release of new WHO recommendations for pregnant women and serodiscordant couples. For example, South Africa, Democratic Republic of Congo, Myanmar and Botswana recently revised their published guidelines to ≤350 cells/mm3 for asymptomatic people living with HIV. Concentration solely on the published or drafted national guidelines for this review is a further limitation, as written policies may not reflect program implementation or practice. China, for instance, has announced plans to implement a countrywide “ART Treatment as Prevention Strategy” wherein ART will be provided to 30,000 discordant couples irrespective of CD4 count.28 Our statistical models use an imperfect proxy variable for guideline implementation and do not capture the correlation between ART coverage and variables like political commitment and prices of ART.
Over the past decade, several important developments in the field of HIV have emerged. Countries have considerably improved the scope of their HIV programs by revising their guidelines to keep abreast with the latest scientific evidence, internationally accepted WHO guidelines, and their ongoing experience in HIV care and treatment. However, slow implementation of these guidelines still poses a key challenge. Our study provides some insights regarding the structural determinants of policy change including the role of per capita income and HIV prevalence. In addition to reviewing the recent evidence and revising its own guidelines, WHO needs to continue working closely with the member states, assisting them in revision and adaption of the guidelines to the local context. ART is a powerful tool for treatment and prevention of HIV and progressive policy and programmatic actions to provide early ART to all eligible people are required to curb the growth of the HIV epidemic.
1. De Cock KM, Jaffe HW, Curran JW. Reflections on 30 years of AIDS. Emerg Infect Dis. 2011;17:1044–1048.
3. Montaner JS, Hogg R, Wood E, et al.. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531–536.
4. Attia S, Egger M, Muller M, et al.. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397–1404.
5. Quinn TC, Wawer MJ, Sewankambo N, et al.. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921–929.
6. Girardi E, Antonucci G, Vanacore P, et al.. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985–1991.
7. Cohen MS, Chen YQ, McCauley M, et al.. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
8. Suthar AB, Lawn SD, Del Amo J, et al.. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001270.
11. WHO. Guidance on Couples HIV Testing and Counselling, Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO; 2012. Available at: http://whqlibdoc.who.int/publications/2012/9789241501972_eng.pdf
. Accessed August 1, 2012.
12. WHO. Programmatic Update—Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants, Executive Summary. Geneva, Switzerland: WHO; 2012. Available at: http://www.who.int/hiv/pub/pmtct_update.pdf
. Accessed August 1, 2012.
19. Barre-Sinoussi F, Chermann JC, Rey F, et al.. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220:868–871.
21. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev. 2010:CD008272.
22. Walensky RP, Wood R, Ciaranello AL, et al.. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2010;7:e1000382.
23. Montaner JS, Lima VD, Barrios R, et al.. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–539.
24. Kitahata MM, Gange SJ, Abraham AG, et al.. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815–1826.
25. Sterne JA, May M, Costagliola D, et al.. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–1363.
26. The HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining conditions in HIV-infected persons in developed countries. Ann Intern Med. 2011;154:509–515.
Keywords:© 2013 Lippincott Williams & Wilkins, Inc.
antiretroviral therapy; CD4; heterosexual transmission; opportunistic infections; prevention of sexual transmission; tuberculosis